Analyst Ratings For Immunocore Hldgs
Portfolio Pulse from Benzinga Insights
Immunocore Holdings (NASDAQ: IMCR) has been analyzed by 7 analysts, showing a range of bullish to bearish sentiments. The average 12-month price target is $82.86, with a high of $100 and a low of $66. Recent analyst actions include maintaining, raising, or lowering ratings and price targets. Immunocore is a biotechnology company with significant revenue growth and strong financial metrics, but a high debt-to-equity ratio.
October 07, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Immunocore Holdings has received mixed analyst ratings, with a current average price target of $82.86. Analysts have maintained, raised, or lowered their ratings and price targets, reflecting varied sentiments. The company's financials show strong revenue growth and profitability, but a high debt-to-equity ratio.
The article provides a detailed analysis of analyst ratings for Immunocore Holdings, showing a range of sentiments from bullish to bearish. The average price target has declined slightly, indicating mixed expectations. The company's financial performance is strong, but the high debt-to-equity ratio poses a risk. These factors suggest a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100